Top ▲

Immune checkpoint modulators C

Overview

Click here for help

« Hide More detailed introduction go icon to follow link

This family contains agents that are able to modulate the regulatory mechanisms that control the immune responses of antigen-specific T cells, including those that are approved immunotherapeutics.

Ligands

Click here for help

Ligands of relevance to immunopharmacology are highlighted in blue

abatacept Show summary » More detailed page

atezolizumab Show summary » More detailed page

avelumab Show summary » More detailed page

belatacept Show summary » More detailed page

cemiplimab Show summary » More detailed page

dostarlimab Show summary » More detailed page

durvalumab Show summary » More detailed page

feladilimab Show summary » More detailed page

gemtuzumab ozogamicin Show summary » More detailed page

inotuzumab ozogamicin Show summary » More detailed page

ipilimumab Show summary » More detailed page

lintuzumab Show summary » More detailed page

lulizumab pegol Show summary » More detailed page

moxetumomab pasudotox Show summary » More detailed page

nivolumab Show summary » More detailed page

pembrolizumab Show summary » More detailed page

penpulimab Show summary » More detailed page

PD-L1 (programmed cell death 1 ligand 1) {Sp: Human} Show summary » More detailed page

relatlimab Show summary » More detailed page

retifanlimab Show summary » More detailed page

sugemalimab Show summary » More detailed page

tislelizumab Show summary » More detailed page

tremelimumab Show summary » More detailed page

vadastuximab talirine Show summary » More detailed page

zimberelimab Show summary » More detailed page

How to cite this family page

Database page citation:

Immune checkpoint modulators. Accessed on 27/09/2023. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=969.